Properties

Code	URL	Description	Type
Specializes		The child code is a more narrow version of the concept represented by the parent code. I.e. Every child concept is also a valid parent concept. Used to allow determination of subsumption. Must be transitive, irreflexive, antisymmetric.	Coding
Generalizes		Inverse of Specializes. Only included as a derived relationship.	Coding
internalId	http://terminology.hl7.org/CodeSystem/utg-concept-properties#v3-internal-id	The internal identifier for the concept in the HL7 Access database repository.	code
notSelectable	http://hl7.org/fhir/concept-properties#notSelectable	Indicates that the code is abstract - only intended to be used as a selector for other concepts	boolean
status	http://hl7.org/fhir/concept-properties#status	Designation of a concept's state. Normally is not populated unless the state is retired.	code

This code system http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution defines the following codes:

Lvl	Code	Display	Definition	internalId	Not Selectable	status
1	_ActSubstanceAdminSubstitutionCode	ActSubstanceAdminSubstitutionCode	Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.	21284	true	active
2	E	equivalent	Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.	23107		active
3	EC	equivalent composition	Description: \r\n\r\nSubstitution occurred or is permitted with another product that is a:\r\n\r\n * pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester\r\n * pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration\r\n\r\nExamples: \r\n\r\n * Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate\r\n * Pharmaceutical equivalent: Lisonpril for Zestril	23108		active
4	BC	brand composition	Description: \r\n\r\nSubstitution occurred or is permitted between equivalent Brands but not Generics\r\n\r\nExamples: \r\n\r\n * Zestril for Prinivil\r\n * Coumadin for Jantoven	23109		active
4	G	generic composition	Description: Substitution occurred or is permitted between equivalent Generics but not Brands\r\n\r\nExamples: \r\n\r\n * Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)	16623		active
3	TE	therapeutic alternative	Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.\r\n\r\nExamples: \r\n\r\n * ranitidine for Tagamet	16624		active
4	TB	therapeutic brand	Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics\r\n\r\n>\r\n\r\nExamples: \r\n\r\n * Zantac for Tagamet	23105		active
4	TG	therapeutic generic	Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands\r\n\r\n>\r\n\r\nExamples: \r\n\r\n * Ranitidine for cimetidine	23106		active
2	F	formulary	Description: This substitution was performed or is permitted based on formulary guidelines.	16625		active
2	N	none	No substitution occurred or is permitted.	16622		active